ArticleEpilepsia2025
Optimizing phenobarbital dosing in critically ill patients with refractory and superrefractory status epilepticus using a population pharmacokinetic model.
Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Model-informed vancomycin precision dosing by population pharmacokinetics combined with machine learning algorithms.British journal of clinical pharmacology · 2026Article
- Toward adaptive therapeutic timing: integration of mechanistic pharmacology and artificial intelligence in precision dosing.Frontiers in pharmacology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCurrent weight-based dosing fails to account for pharmacokinetic variability in refractory and superrefractory status epilepticus (RSE, SRSE). However, understanding pharmacokinetics in critically ill patients with varying degrees of organ dysfunction can improve both safety and efficacy. Hence, this study aims to quantify key pharmacokinetic variabilities to enable individualized dosing in RSE and SRSE.
methodsPatients with RSE and SRSE admitted to a neurointensive care unit of a tertiary academic center were retrospectively screened for therapeutic drug monitoring (TDM) samples of phenobarbital. Demographics, laboratory data, comedication, and dosing history were collected from electronic health records. Using a nonlinear mixed effects modeling approach via MONOLIX, a population pharmacokinetic model was developed. Optimal dosing regimens were simulated based on estimated parameters, with target attainment calculated for trough plasma phenobarbital concentrations within 18-40 mg/L.
resultsThirty-seven patients contributed 301 TDM samples. Oral bioavailability (96%), volume of distribution (V; 34.3 L), and total body clearance (CL; .38 L/h) were consistent with nonintensive care literature data. Ideal body weight (IBW) implemented as allometric scaling was the only significant covariate improving model fit, demonstrating a positive correlation with the required phenobarbital dose. Simulations identified optimal 12-h dosing strategies. Oral and intravenous dosing showed minor differences in loading doses but identical maintenance doses, with no significant impact on target attainment for both administration methods. As shown by the coefficients of variation (CVs), intensive care patients exhibited high interindividual (81.36% CV on V, 41.36% CV on CL) and interoccasion variability (36.85% CV on CL), resulting in low target attainment in simulated patients (~40%). SIGNIFICANCE: The pharmacokinetic model characterized phenobarbital pharmacokinetics in patients with RSE and SRSE, showing high oral bioavailability and IBW's impact on V and CL. High pharmacokinetic variability led to low target attainment. Model-informed precision dosing might improve target attainment in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.